Epigenomics AG
Other OTCTotal Valuation
Epigenomics AG carries a market capitalization of 1.00M, placing it among publicly traded companies globally. Its enterprise value stands at -2.67M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.00M |
| Enterprise Value | -2.67M |
Share Statistics
Epigenomics AG currently has 853,285.00 shares outstanding.
| Shares Outstanding | 853,285.00 |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 1.24, and the price-to-book ratio stands at -0.01.
| PE Ratio | N/A |
| PS Ratio | 1.24 |
| PB Ratio | -0.01 |
| P/TBV Ratio | 0.30 |
| P/FCF Ratio | -0.07 |
| P/OCF Ratio | -0.06 |
Enterprise Valuation
| EV / Sales | 10.67 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Epigenomics AG maintains a current ratio of 1.93, meaning it holds 1.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 18.65, indicating elevated leverage, while an interest coverage ratio of -180.60 demonstrates limited ability to service its debt obligations.
| Current Ratio | 1.93 |
| Quick Ratio | 1.67 |
| Debt / Equity | 18.65 |
| Debt / EBITDA | -0.02 |
| Interest Coverage | -180.60 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -131.18 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 2.73 |
Taxes
| Income Tax | -77,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
Epigenomics AG's stock has gained approximately 0% over the past 52 weeks. The 50-day moving average sits at 1.12, while the 200-day moving average is 1.03.
| Beta (5Y) | N/A |
| 52-Week Price Change | 0% |
| 50-Day Moving Average | 1.12 |
| 200-Day Moving Average | 1.03 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Epigenomics AG generated 448,000.00 in revenue and converted that into -16.29M in net income, yielding earnings per share of -19.36. EBITDA reached -18.24M, while operating income came in at -18.24M.
| Revenue | 448,000.00 |
| Gross Profit | 343,000.00 |
| Operating Income | -18.24M |
| Pretax Income | -16.37M |
| Net Income | -16.29M |
| EBITDA | -18.24M |
| EBIT | -18.24M |
| Earnings Per Share (EPS) | -19.36 |
Balance Sheet
Epigenomics AG holds 3.58M in cash and equivalents against 356,000.00 in total debt, resulting in a net debt position of -3.58M. Total book value stands at -100.37M, with working capital of 2.01M providing operational flexibility.
| Cash & Cash Equivalents | 3.58M |
| Total Debt | 356,000.00 |
| Net Debt | -3.58M |
| Equity (Book Value) | -100.37M |
| Book Value Per Share | -119.28 |
| Working Capital | 2.01M |
Cash Flow
Epigenomics AG produced -9.57M in operating cash flow over the past twelve months. After subtracting -1.03M in capital expenditures, free cash flow totaled -10.60M - equivalent to -12.60 per share.
| Operating Cash Flow | -9.57M |
| Capital Expenditures | -1.03M |
| Free Cash Flow | -10.60M |
| FCF Per Share | -12.60 |
Margins
Epigenomics AG operates with a gross margin of 76.56, reflecting its pricing power and cost economics. The operating margin of -4,071.65 and net profit margin of -3,636.16 provide insight into operational efficiency.
| Gross Margin | 76.56 |
| Operating Margin | -4,071.65 |
| Pretax Margin | -3,653.35 |
| Profit Margin | -3,636.16 |
| EBITDA Margin | -4,071.65 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | 21.79 |
| FCF Yield | -1,537.81 |
Stock Splits
Epigenomics AG's most recent stock split took place on December 8, 2023 with a 5:1 split ratio.
| Last Split Date | 12/8/2023 |
| Split Ratio | 5:1 |
Scores
Epigenomics AG posts an Altman Z-Score of -48.82, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -48.82 |